

Oversikt over prospektive studier som inkluderer pasienter i Norge

Kortnavn	Studietittel	Intervensjon/observasjon	Behandlingssituasjon	Undergruppe	Ansvarlig	Deltagende sykehus	Inklusjons og eksklusjonskriterier
Etter TARGIT	Kvalitetssikringsprosjekt etter Targit studien: Intraoperativ stråleterapi for lavrisikopasienter	Stråleterapi	Adjuvant strålebehandling	Lavrisko	Hilde Krogstad	St. Olav	<a href="https://nbcg.no/pagaende-studier-apne-for-inklusjon/intraoperativ-stralebehandling-av-brytkeftpasienter-en-kvalitetssikringsstudie/">https://nbcg.no/pagaende-studier-apne-for-inklusjon/intraoperativ-stralebehandling-av-brytkeftpasienter-en-kvalitetssikringsstudie/</a>
T-REX	Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases; an open, multicenter, randomized non-inferiority phase 3-trial (Ingvil Mjaaland)	Stråleterapi	Adjuvant strålebehandling	pN1 (1-2+ SN)	Ingvil Mjaaland	UNN, NLSH, Ålesund SH, GUS, SUS, Sørlandet SH, OUS	<a href="https://clinicaltrials.gov/study/NCT05634889?cond=Breast%20Cancer&amp;term=t-rex&amp;rank=1#participation-criteria">https://clinicaltrials.gov/study/NCT05634889?cond=Breast%20Cancer&amp;term=t-rex&amp;rank=1#participation-criteria</a>
TAORMINA	Treatment of Oligometastatic breast cancer – a randomized phase-3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1. line treatment (Vidar Flote)	Stråleterapi	Metastatisk strålebehandling	Oligometastaser	Vidar Flote	UNN, St. Olav, HUS, SUS, OUS	<a href="https://clinicaltrials.gov/study/NCT05377047?cond=Breast%20Cancer&amp;term=taormina&amp;rank=1">https://clinicaltrials.gov/study/NCT05377047?cond=Breast%20Cancer&amp;term=taormina&amp;rank=1</a>
OPTIMA	OPTIMA (EMIT2). Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. Bruk av Prosigna test til adjuvant behandlingsbeslutning (Bjørn Naume)	Prosignatest basert intervensjon	Adjuvant systemisk behandling	HR+HER2- pN1-2	Bjørn Naume	UNN, NLSH, St. Olav, Ålesund SH, HUS, SUS, Sørlandet SH, Kalnes SH, OUS	<a href="https://nbcg.no/pagaende-studier-apne-for-inklusjon/optima/">https://nbcg.no/pagaende-studier-apne-for-inklusjon/optima/</a>
AXSANA	AXillary Surgery After NeoAdjuvant treatment) (Ellen Schlichting)	Axillekirurgi	Primærbehandling	Alle	Ellen Schlichting	OUS, VV Drammen, St. Olav, UNN, SUS	<a href="https://clinicaltrials.gov/study/NCT04373655?cond=Breast%20Cancer&amp;term=axsana&amp;rank=1#participation-criteria">https://clinicaltrials.gov/study/NCT04373655?cond=Breast%20Cancer&amp;term=axsana&amp;rank=1#participation-criteria</a>
NEOLETRIB	Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole	Endokrin behandling	Neoadjuvant behandling	HR+HER2-	Jürgen Geisler	Ahus	<a href="https://nbcg.no/pagaende-studier-apne-for-inklusjon/neoletrib/">https://nbcg.no/pagaende-studier-apne-for-inklusjon/neoletrib/</a>
NAPEER	NeoAdjuvant Personalized therapy in Estrogen Receptor positive breast cancer (NAPEER) - An open label phase II trial of endocrine treatment with or without capivasertib, followed by response assessment before neoadjuvant chemotherapy with bevacizumab (if VIPR signature positive). (Olav Engebråten)	Capivasertib og bevacizumab	Neoadjuvant behandling	HR+HER2-	Olav Engebråten	OUS	<a href="https://clinicaltrials.gov/study/NCT02546232?cond=Breast%20Cancer&amp;term=engebraaten&amp;rank=1#participation-criteria">https://clinicaltrials.gov/study/NCT02546232?cond=Breast%20Cancer&amp;term=engebraaten&amp;rank=1#participation-criteria</a>
SERENAG	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitors (Palbociclib or Abemaciclib) vs Continuing NSAI + CDK4/6 Inhibitors in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Clinical or Radiological Progression During 1L Treatment with NSAI + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study (Alina Porojnicu)	Camizestrant	Metastatisk - med ctDNA monitorering	HR+HER2-	Alina Porojnicu	VV Drammen, OUS, SUS	<a href="https://clinicaltrials.gov/study/NCT04964934?cond=Breast%20Cancer&amp;term=serena-6&amp;rank=1#participation-criteria">https://clinicaltrials.gov/study/NCT04964934?cond=Breast%20Cancer&amp;term=serena-6&amp;rank=1#participation-criteria</a>
IMPRESS	Improving public cancer care by implementing precision medicine in Norway - A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer	Diverse basert på påviste "targetable" mutasjoner	Metastatisk hvor behandlingsmuligheter er få	Alle typer kreft	Åslaug Helland	Landsdekkende	<a href="https://clinicaltrials.gov/study/NCT04817956?cond=Cancer&amp;term=IMPRESS&amp;rank=1">https://clinicaltrials.gov/study/NCT04817956?cond=Cancer&amp;term=IMPRESS&amp;rank=1</a>